{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:21:07Z","timestamp":1765808467134,"version":"3.40.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00105-025-05495-z","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T18:33:50Z","timestamp":1743878030000},"page":"267-276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nagelpsoriasis \u2013\u00a0schmerzhaft und doch untertherapiert","Nail psoriasis\u2014painful and yet undertreated"],"prefix":"10.1007","volume":"76","author":[{"given":"Katharina","family":"Assaf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel Georg Peter","family":"Irintchev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Wilsmann-Theis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"5495_CR1","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/j.1365-2133.2010.09831.x","volume":"163","author":"M Augustin","year":"2010","unstructured":"Augustin\u00a0M, Reich\u00a0K, Blome\u00a0C et\u00a0al (2010) Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 163:580\u2013585","journal-title":"Br J Dermatol"},{"key":"5495_CR2","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.2147\/CCID.S417679","volume":"16","author":"T Battista","year":"2023","unstructured":"Battista\u00a0T, Scalvenzi\u00a0M, Martora\u00a0F et\u00a0al (2023) Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments. Clin Cosmet Investig Dermatol 16:1899\u20131932","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"5495_CR3","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40257-021-00622-7","volume":"22","author":"C Blome","year":"2021","unstructured":"Blome\u00a0C, Augustin\u00a0M, Klein\u00a0TM (2021) Nail Psoriasis and Quality-of-Life Measurement in Clinical Trials: Call for the Use of Nail-Specific Instruments. Am J Clin Dermatol 22:747\u2013755","journal-title":"Am J Clin Dermatol"},{"key":"5495_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ad.2022.01.032","volume":"113","author":"E Canal-Garcia","year":"2022","unstructured":"Canal-Garcia\u00a0E, Bosch-Amate\u00a0X, Belinchon\u00a0I et\u00a0al (2022) Nail Psoriasis. Actas Dermosifiliogr 113:481\u2013490","journal-title":"Actas Dermosifiliogr"},{"key":"5495_CR5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3899\/jrheum.211043","volume":"49","author":"LC Coates","year":"2022","unstructured":"Coates\u00a0LC, Corp\u00a0N, Van Der Windt\u00a0DA et\u00a0al (2022) GRAPPA Treatment Recommendations: 2021 Update. J\u00a0Rheumatol 49:52\u201354","journal-title":"J Rheumatol"},{"key":"5495_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s13555-021-00654-1","volume":"12","author":"C Conrad","year":"2022","unstructured":"Conrad\u00a0C, Ortmann\u00a0CE, Vandemeulebroecke\u00a0M et\u00a0al (2022) Nail Involvement as a\u00a0Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis. Dermatol Ther (Heidelb) 12:233\u2013241","journal-title":"Dermatol Ther (Heidelb)"},{"key":"5495_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1001\/jamadermatol.2014.2983","volume":"151","author":"JJ Crowley","year":"2015","unstructured":"Crowley\u00a0JJ, Weinberg\u00a0JM, Wu\u00a0JJ et\u00a0al (2015) Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol 151:87\u201394","journal-title":"JAMA Dermatol"},{"key":"5495_CR8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s13555-021-00523-x","volume":"11","author":"E Hadeler","year":"2021","unstructured":"Hadeler\u00a0E, Mosca\u00a0M, Hong\u00a0J et\u00a0al (2021) Nail Psoriasis: A\u00a0Review of Effective Therapies and Recommendations for Management. Dermatol Ther (Heidelb) 11:799\u2013831","journal-title":"Dermatol Ther (Heidelb)"},{"key":"5495_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/PTT.S126281","volume":"7","author":"E Haneke","year":"2017","unstructured":"Haneke\u00a0E (2017) Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management. Psoriasis 7:51\u201363","journal-title":"Psoriasis"},{"key":"5495_CR10","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1111\/jdv.17387","volume":"35","author":"S Hudgens","year":"2021","unstructured":"Hudgens\u00a0S, Rich\u00a0P, Geng\u00a0Z et\u00a0al (2021) Development and validation of the Physician\u2019s Global Assessment of Fingernail Psoriasis. J\u00a0Eur Acad Dermatol Venereol 35:2324\u20132330","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5495_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jaad.2023.11.024","volume":"90","author":"JK Hwang","year":"2024","unstructured":"Hwang\u00a0JK, Grover\u00a0C, Iorizzo\u00a0M et\u00a0al (2024) Nail psoriasis and nail lichen planus: Updates on diagnosis and management. J\u00a0Am Acad Dermatol 90:585\u2013596","journal-title":"J Am Acad Dermatol"},{"key":"5495_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s12016-021-08896-9","volume":"61","author":"C Ji","year":"2021","unstructured":"Ji\u00a0C, Wang\u00a0H, Bao\u00a0C et\u00a0al (2021) Challenge of Nail Psoriasis: An Update Review. Clin Rev Allergy Immunol 61:377\u2013402","journal-title":"Clin Rev Allergy Immunol"},{"key":"5495_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s00105-011-2228-4","volume":"63","author":"C Kahl","year":"2012","unstructured":"Kahl\u00a0C, Hansen\u00a0B, Reich\u00a0K (2012) Nail psoriasis\u2014an ignored disorder. Pathogenesis, diagnosis and therapy. Hautarzt 63:184\u2013191","journal-title":"Hautarzt"},{"key":"5495_CR14","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jaad.2014.02.010","volume":"70","author":"KM Klaassen","year":"2014","unstructured":"Klaassen\u00a0KM, Van De Kerkhof\u00a0PC, Bastiaens\u00a0MT et\u00a0al (2014) Scoring nail psoriasis. J\u00a0Am Acad Dermatol 70:1061\u20131066","journal-title":"J Am Acad Dermatol"},{"key":"5495_CR15","doi-asserted-by":"publisher","first-page":"adv00214","DOI":"10.2340\/00015555-3545","volume":"100","author":"G Kokolakis","year":"2020","unstructured":"Kokolakis\u00a0G, Bachmann\u00a0F, Wolk\u00a0K et\u00a0al (2020) Efficacy of Adalimumab for Nail Psoriasis During 24\u00a0Months of Continuous Therapy. Acta Derm Venereol 100:adv214","journal-title":"Acta Derm Venereol"},{"key":"5495_CR16","first-page":"e389","volume":"36","author":"LE Kristensen","year":"2022","unstructured":"Kristensen\u00a0LE, Soliman\u00a0AM, Papp\u00a0K et\u00a0al (2022) Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1. J\u00a0Eur Acad Dermatol Venereol 36:e389\u2013e392","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5495_CR17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3899\/jrheum.190923","volume":"48","author":"PJ Mease","year":"2021","unstructured":"Mease\u00a0PJ, Liu\u00a0M, Rebello\u00a0S et\u00a0al (2021) Association of Nail Psoriasis With Disease Activity Measures and Impact in Psoriatic Arthritis: Data From the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry. J\u00a0Rheumatol 48:520\u2013526","journal-title":"J Rheumatol"},{"key":"5495_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1590\/S0365-05962012000200003","volume":"87","author":"RC Nakamura","year":"2012","unstructured":"Nakamura\u00a0RC, Abreu\u00a0L, Duque-Estrada\u00a0B et\u00a0al (2012) Comparison of nail lacquer clobetasol efficacy at 0.05\u202f%, 1\u202f% and 8\u202f% in nail psoriasis treatment: prospective, controlled and randomized pilot study. An Bras Dermatol 87:203\u2013211","journal-title":"An Bras Dermatol"},{"key":"5495_CR19","first-page":"934","volume":"19","author":"A Nast","year":"2021","unstructured":"Nast\u00a0A, Altenburg\u00a0A, Augustin\u00a0M et\u00a0al (2021) Not Available. J\u00a0Dtsch Dermatol Ges 19:934\u2013951","journal-title":"J Dtsch Dermatol Ges"},{"key":"5495_CR20","doi-asserted-by":"crossref","unstructured":"Peng YT, Yu RT, Chen AJ et\u00a0al (2023) Predicting the Risk of Nail Involvement in Psoriasis Patients: Development and Assessment of a\u00a0Predictive Nomogram. Diagnostics 13:","DOI":"10.3390\/diagnostics13040633"},{"key":"5495_CR21","first-page":"1","volume":"2","author":"MA Radtke","year":"2011","unstructured":"Radtke\u00a0MA, Langenbruch\u00a0AK, Schafer\u00a0I et\u00a0al (2011) Nail psoriasis as a\u00a0severity indicator: results from the PsoReal study. Patient Relat Outcome Meas 2:1\u20136","journal-title":"Patient Relat Outcome Meas"},{"issue":"1","key":"5495_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1468-3083.2009.03364.x","volume":"23","author":"K Reich","year":"2009","unstructured":"Reich\u00a0K (2009) Approach to managing patients with nail psoriasis. J\u00a0Eur Acad Dermatol Venereol 23(1):15\u201321","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5495_CR23","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1080\/09546634.2021.1892024","volume":"33","author":"K Reich","year":"2022","unstructured":"Reich\u00a0K, Conrad\u00a0C, Kristensen\u00a0LE et\u00a0al (2022) Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. J\u00a0Dermatolog Treat 33:1652\u20131660","journal-title":"J Dermatolog Treat"},{"key":"5495_CR24","first-page":"adv00318","volume":"100","author":"J Szebenyi","year":"2020","unstructured":"Szebenyi\u00a0J, Gede\u00a0N, Hegyi\u00a0P et\u00a0al (2020) Efficacy of Biologics Targeting Tumour Necrosis Factor-alpha, Interleukin-17 -12\/23, -23 and Small Molecules Targeting JAK and PDE4 in the Treatment of Nail Psoriasis: A\u00a0Network Meta-analysis. Acta Derm Venereol 100:adv318","journal-title":"Acta Derm Venereol"},{"key":"5495_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13075-023-03138-z","volume":"25","author":"W Tillett","year":"2023","unstructured":"Tillett\u00a0W, Egeberg\u00a0A, Sonkoly\u00a0E et\u00a0al (2023) Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a\u00a0post hoc analysis of the VOYAGE 2 randomized trial. Arthritis Res Ther 25:169","journal-title":"Arthritis Res Ther"},{"key":"5495_CR26","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.2147\/DDDT.S136986","volume":"11","author":"A Ventura","year":"2017","unstructured":"Ventura\u00a0A, Mazzeo\u00a0M, Gaziano\u00a0R et\u00a0al (2017) New insight into the pathogenesis of nail psoriasis and overview of treatment strategies. Drug Des Devel Ther 11:2527\u20132535","journal-title":"Drug Des Devel Ther"},{"key":"5495_CR27","first-page":"509","volume":"113","author":"U Wollina","year":"2016","unstructured":"Wollina\u00a0U, Nenoff\u00a0P, Haroske\u00a0G et\u00a0al (2016) The Diagnosis and Treatment of Nail Disorders. Dtsch \u00c4rztebl Int 113:509\u2013518","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"5495_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5021\/ad.24.026","volume":"36","author":"SW Youn","year":"2024","unstructured":"Youn\u00a0SW (2024) Nail Psoriasis: Clinical Features and Severity Assessment. Ann Dermatol 36:191\u2013196","journal-title":"Ann Dermatol"},{"key":"5495_CR29","doi-asserted-by":"publisher","first-page":"620562","DOI":"10.3389\/fmed.2021.620562","volume":"8","author":"X Zhang","year":"2021","unstructured":"Zhang\u00a0X, Xie\u00a0B, He\u00a0Y (2021) Efficacy of Systemic Treatments of Nail Psoriasis: A\u00a0Systemic Literature Review and Meta-Analysis. Front Med 8:620562","journal-title":"Front Med"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-025-05495-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-025-05495-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-025-05495-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T13:49:57Z","timestamp":1745848197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-025-05495-z"}},"subtitle":["Von der Pathogenese zur Therapie","From pathogenesis to therapy"],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["5495"],"URL":"https:\/\/doi.org\/10.1007\/s00105-025-05495-z","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"type":"print","value":"2731-7005"},{"type":"electronic","value":"2731-7013"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"5 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Assaf hat finanzielle Unterst\u00fctzung (Reisekostenerstattung und\/oder Zusch\u00fcsse und\/oder Teilnahme an klinischen Studien) von den folgenden Unternehmen erhalten: AbbVie, Almirall-Hermal, Amgen, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Incyte, Janssen-Cilag, Leo, Lilly, Novartis, Pfizer, Sanofi, Butterfly IQ, UCB. D.\u00a0Wilsmann-Theis war Beraterin und\/oder erhielt Referentenhonorare und\/oder Reisekostenerstattungen und\/oder Zusch\u00fcsse sowie nahm an klinischen Studien der nachfolgenden Unternehmen teil: AbbVie, Almirall-Hermal, Amgen, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Forward Pharma, GlaxoSmithKline, Incyte, Janssen-Cilag, Klinge Pharma, Leo, Eli Lilly, Medac, Merck, Moonlake, Novartis, Pfizer und UCB. M.G.P.\u00a0Irintchev hat keine Interessenkonflikte bez\u00fcglich finanzieller Unterst\u00fctzung darzulegen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Die Autoren erkl\u00e4ren die Einhaltung ethischer Richtlinien bez\u00fcglich der Ver\u00f6ffentlichung. Einverst\u00e4ndnis der Patient\/innen: Die Zustimmung zur Ver\u00f6ffentlichung der Patientenfotos und der medizinischen Daten wurde von den Autoren zum Zeitpunkt der Einreichung des Artikels bei der Zeitschrift gegeben. Darin wird erkl\u00e4rt, dass die Patienten ihr Einverst\u00e4ndnis zur Ver\u00f6ffentlichung ihrer Fotos und medizinischen Daten in gedruckter Form und online gegeben haben, und zwar mit dem Wissen, dass diese Informationen \u00f6ffentlich zug\u00e4nglich sein k\u00f6nnen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}